Answers are grounded in this paper and cite their sources.
Based on our preclinical results, we suggest analyzing the predictive value of the BCRP in breast cancer patients scheduled for irinotecan treatment. Moreover, LMP400 should be tested in a clinical setting in breast cancer patients with resistance to irinotecan.
No takes yet. Share an insight, caveat, or question.
Jandu et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: